Thursday, December 3, 2020
Home Latest Pharma-News Mallinckrodt intiates retrospective study for inhaled therapy in COVID-19

Mallinckrodt intiates retrospective study for inhaled therapy in COVID-19

 Nov. 10, 2020: Mallinckrodt plc, a global biopharmaceutical company announced initiation of a retrospective chart review study, titled “Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)” to collect real-world data on the use of INOmax® (nitric oxide) gas, for inhalation therapy in patients with respiratory complications associated with the novel coronavirus SARS-CoV-2 (COVID-19).  

INOmax is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.

- Advertisement -

The safety and efficacy of INOmax to treat lung complications associated with COVID-19 has not been evaluated or established by the U.S. Food and Drug Administration.

“We hope this retrospective chart review will help to further extend our understanding of the use of inhaled nitric oxide,” said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt.

Mallinckrodt will partner with Pharmerit – an OPEN Health company – to collect data from approximately 200 hospitalized adult patients with a confirmed diagnosis of COVID-19 who were treated with INOmax for pulmonary complications associated with COVID-19 for at least 24 hours between January 1, 2020 and July 31, 2020.

Patient data will be reviewed for the period from hospital admission to 30 days post-discharge.

The primary objectives of the study are as follows:

  • Describe the disease course in patients initiating INOmax for management of COVID-19 symptoms
  • Assess the clinical outcomes of patients who have received INOmax early (high P/F ratio or low OI) vs late (low P/F ratio or high OI)
  • Describe the demographic and clinical characteristics of patients hospitalized with COVID-19 and treated with INOmax
  • Describe treatments and procedures, and during the initial hospitalization, and survival at 30 days post-discharge in patients who are treated with INOmax
  • Assess selected complications and adverse events as documented in the medical chart of initial hospitalization 
  • Evaluate healthcare resource use during initial hospitalization

COVID-19 is a contagious respiratory illness caused by a novel coronavirus. Patients with COVID-19 have mild to severe respiratory illness that can include symptoms such as cough, fever and shortness of breath.

In severe cases, COVID-19 can cause acute respiratory distress syndrome (ARDS) – a disorder in which fluid leaks into the lungs, making breathing difficult or impossible – and can lead to multi-organ failure and sometimes death.

To date, more than 200,000 patients in the U.S. have died from COVID-19.

INOmax has been on the market in the U.S. since 2000 and is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Please see Important Safety Information below. The safety and efficacy of INOmax and iNO for pulmonary complications associated with COVID-19 have not been established.

INDICATION

INOmax® (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

    https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=27011

LEAVE A REPLY

Please enter your comment!
Please enter your name here

10 − three =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...